Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 5
2007 22
2008 22
2009 16
2010 21
2011 20
2012 23
2013 22
2014 29
2015 20
2016 15
2017 17
2018 13
2019 9
2020 10
2021 19
2022 7
2023 10
2024 7
2025 9
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Results by year

Filters applied: . Clear all
Page 1
Epoetin Beta.
[No authors listed] [No authors listed] 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30277694 Free Books & Documents. Review.
Methoxy polyethylene glycol-epoetin beta is a synthetic form of erythropoietin that slowly releases the active drug, epoetin beta (recombinant human erythropoietin). Erythropoietin is a normal component of human milk. The excretion of exogenous …
Methoxy polyethylene glycol-epoetin beta is a synthetic form of erythropoietin that slowly releases the a …
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Chung EY, Palmer SC, Saglimbene VM, Craig JC, Tonelli M, Strippoli GF. Chung EY, et al. Cochrane Database Syst Rev. 2023 Feb 13;2(2):CD010590. doi: 10.1002/14651858.CD010590.pub3. Cochrane Database Syst Rev. 2023. PMID: 36791280 Free PMC article.
OBJECTIVES: To compare the efficacy and safety of ESAs (epoetin alfa, epoetin beta, darbepoetin alfa, methoxy polyethylene glycol-epoetin beta, and biosimilar ESAs against each other, placebo, or no treatment) to treat anaemia in adults with CKD …
OBJECTIVES: To compare the efficacy and safety of ESAs (epoetin alfa, epoetin beta, darbepoetin alfa, methoxy polyethylene …
Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.
Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB. Locatelli F, et al. Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1701-1710. doi: 10.2215/CJN.01380219. Epub 2019 Aug 16. Clin J Am Soc Nephrol. 2019. PMID: 31420350 Free PMC article. Clinical Trial.
We compared cardiovascular outcomes and all-cause mortality associated with monthly methoxy polyethylene glycol-epoetin beta with those of the shorter-acting agents epoetin alfa/beta and darbepoetin alfa in patients with anemia of CKD. ...RESULT …
We compared cardiovascular outcomes and all-cause mortality associated with monthly methoxy polyethylene glycol-epoe …
Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure.
Schmid H. Schmid H. Expert Rev Hematol. 2016 Jan;9(1):5-20. doi: 10.1586/17474086.2016.1112734. Epub 2015 Nov 17. Expert Rev Hematol. 2016. PMID: 26573694 Review.
Since more than two decades erythropoiesis-stimulating agents are the main pillar for treatment of anemia associated with chronic kidney disease. Methoxy polyethylene glycol-epoetin beta (MPG-EPO), also called continuous erythropoietin …
Since more than two decades erythropoiesis-stimulating agents are the main pillar for treatment of anemia associated with chronic kidney dis …
The resistance to methoxy polyethylene glycol-epoetin beta in anemic patients of end-stage renal disease.
Abood SJ, Abdulsahib WK, Al-Radeef MY. Abood SJ, et al. Heliyon. 2023 Feb 14;9(2):e13747. doi: 10.1016/j.heliyon.2023.e13747. eCollection 2023 Feb. Heliyon. 2023. PMID: 36865462 Free PMC article.
AIM: This research aimed to investigate the relation between resistance to the methoxy polyethylene glycol-epoetin beta (ME-beta) and angiotensin-converting enzyme (ACE) gene polymorphism. ...
AIM: This research aimed to investigate the relation between resistance to the methoxy polyethylene glycol-epoetin …
Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease.
Curran MP, McCormack PL. Curran MP, et al. Drugs. 2008;68(8):1139-56. doi: 10.2165/00003495-200868080-00009. Drugs. 2008. PMID: 18484803 Review.
Methoxy polyethylene glycol-epoetin beta (Mircera) is a continuous erythropoietin receptor activator, with a long half-life (approximately 130 hours). ...Methoxy polyethylene glycol-epoetin …
Methoxy polyethylene glycol-epoetin beta (Mircera) is a continuous erythropoietin recept …
Erythropoietin Stimulating Agents.
Schoener B, Borger J. Schoener B, et al. 2024 Jul 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. 2024 Jul 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. PMID: 30725682 Free Books & Documents.
Erythropoiesis-stimulating agents (ESAs), such as epoetin, darbepoetin, and methoxy polyethylene glycol-epoetin beta, are pharmacologically synthesized, recombinant forms of EPO. ...
Erythropoiesis-stimulating agents (ESAs), such as epoetin, darbepoetin, and methoxy polyethylene glycol-epoetin …
Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
Piotr B, Mariusz S, Jacek R. Piotr B, et al. Curr Pharm Biotechnol. 2017;18(4):303-308. doi: 10.2174/1389201018666170127104801. Curr Pharm Biotechnol. 2017. PMID: 28137221 Review.
Literature data indicate the usefulness of long-acting ESAs in treatment of anemia in non-dialysis CKD patients. In particular, continuous erythropoietin receptor activator seems to be a good choice in these patients because of its efficiency, safety a …
Literature data indicate the usefulness of long-acting ESAs in treatment of anemia in non-dialysis CKD patients. In particular, continuou …
Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial.
Roger SD, Wong CM, Vejakama P, Rahardjo KD, Hsu BG, Lee CM, Wu IW, Lee CC, Situmorang TD, Krisanapan P, Mazlan SA, Peng YS, Sarwono J, De Asis N, Solimen D, Jonny, Sangthawan P, Chen JB, Wang CL, Chung S, Villaflor AJ, Yang CW, Kan WC, Yang Y, Rubio-Bicol J, Yan LY, Lee SH, Chiu YW, Chen CH, Na KY, Hassah WHHW, Kang YS, Choi BS, Aquitania G, Na KR, Wu MS, Ahmad MK, Isidto R, Wu V, Leong GB, Sung JM, Noppakun K, Chou KJ, Abdul Wahab MZ, Shin SJ, Nugroho P. Roger SD, et al. Nephrology (Carlton). 2025 May;30(5):e70046. doi: 10.1111/nep.70046. Nephrology (Carlton). 2025. PMID: 40369895 Free PMC article. Clinical Trial.
CONCLUSION: Efepoetin alfa demonstrated non-inferiority to methoxy polyethylene glycol-epoetin beta in correcting anaemia and maintaining haemoglobin (Hb) levels among stage 3 and 4 CKD patients. Moreover, the safety profile of efepoetin alfa wa …
CONCLUSION: Efepoetin alfa demonstrated non-inferiority to methoxy polyethylene glycol-epoetin beta in co …
Optimizing SAR-PAGE.
Reihlen P, Blobel M, Kempkes R, Reichel C, Völker Schänzer E, Majer B, Schänzer W. Reihlen P, et al. Drug Test Anal. 2015 Nov-Dec;7(11-12):1014-6. doi: 10.1002/dta.1915. Epub 2015 Nov 26. Drug Test Anal. 2015. PMID: 26607413 No abstract available.
280 results